Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Intermittent Theta-Burst Stimulation (iTBS) as an add-on to Eye Movement Desensitization and Reprocessing (EMDR) in the Treatment of Post-traumatic Stress Disorder (PTSD)

7 de julio de 2026 actualizado por: Pernille Kølbæk, Aarhus University Hospital

Intermittent Theta-Burst Stimulation (iTBS) as an add-on to Eye Movement Desensitization and Reprocessing (EMDR) in the Treatment of Post-traumatic Stress Disorder (PTSD): An Open-label Pilot Study

This open-label pilot study will evaluate the feasibility, safety, tolerability, and preliminary clinical outcomes of adding intermittent theta-burst stimulation (iTBS) to Eye Movement Desensitization and Reprocessing (EMDR) therapy in adults with post-traumatic stress disorder (PTSD), who show insufficient improvement after an initial course of EMDR.

Participants will receive weekly EMDR therapy. After seven EMDR sessions, treatment response will be assessed using the Clinical Global Impression-Improvement scale (CGI-I). Participants with insufficient response will receive add-on iTBS targeted to the right dorsolateral prefrontal cortex (DLPFC) for four weeks while continuing EMDR. Feasibility outcomes include adherence, treatment completion, and dropout rates. Clinical outcomes will include clinician-rated and self-reported measures of PTSD symptoms, depressive symptoms, well-being, and adverse events.

Descripción general del estudio

Estado

Aún no reclutando

Condiciones

Intervención / Tratamiento

Descripción detallada

Post-traumatic stress disorder (PTSD) is a disabling psychiatric condition characterized by intrusive traumatic memories, avoidance behaviors, negative alterations in cognition and mood, and persistent hyperarousal. Although trauma-focused psychotherapies such as Eye Movement Desensitization and Reprocessing (EMDR) are recommended as first-line treatments, a substantial proportion of patients continue to meet diagnostic criteria for PTSD despite receiving evidence-based psychotherapy.

Intermittent theta-burst stimulation (iTBS), a brief form of repetitive transcranial magnetic stimulation (rTMS), has demonstrated preliminary efficacy in reducing PTSD symptoms and offers practical advantages due to its short treatment duration.

The present study aims to investigate whether iTBS can be feasibly integrated as an adjunctive intervention for patients who do not respond sufficiently to EMDR therapy alone. This is an investigator-initiated, open-label feasibility study conducted within psychiatric services in the Central Denmark Region.

Eligible adults aged 18 to 70 years with a diagnosis of PTSD, who are referred for EMDR treatment, will be enrolled. Participants will receive standardized EMDR therapy consisting of sixteen weekly 90-minute sessions. Following completion of seven EMDR sessions, treatment response will be evaluated using the Clinical Global Impression-Improvement (CGI-I) scale. Participants rated as having insufficient improvement (CGI-I score ≥3) will be offered add-on iTBS.

The iTBS intervention will be delivered to the right DLPFC using a MagPro R30 stimulator and Cool-B70 coil. Treatment will consist of one daily iTBS session administered five days per week over four weeks for a total of 20 sessions. Participants will continue weekly EMDR therapy throughout the iTBS phase and subsequent follow-up period.

The primary objectives are to evaluate the safety, tolerability, and feasibility of the combined EMDR+iTBS intervention. Feasibility outcomes include treatment adherence, treatment completion rates, and dropout rates. Secondary outcomes include adverse events and changes in PTSD symptom severity measured using clinician-rated and self-reported instruments.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

15

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Pernille Kølbæk, MD PhD
  • Número de teléfono: 004561397432
  • Correo electrónico: perpet@rm.dk

Copia de seguridad de contactos de estudio

  • Nombre: Ana Lisa Carmo, Psychiatrist
  • Número de teléfono: 0045 61155056
  • Correo electrónico: ANAMAR@rm.dk

Ubicaciones de estudio

      • Aarhus N, Dinamarca
        • Aarhus University Hospital
        • Contacto:
          • Pernille Kølbæk, MD PhD
          • Número de teléfono: 004561397432
          • Correo electrónico: perpet@rm.dk
        • Contacto:
          • Ana Lisa Carmo, Psychiatrist
          • Número de teléfono: 0045 61155056
          • Correo electrónico: ANAMAR@rm.dk
        • Investigador principal:
          • Ana Lisa Carmo, Psychiatrist
      • Horsens, Dinamarca
        • Regional Psychiatry Horsens
        • Contacto:
          • Pernille Kølbæk, MD PhD
          • Número de teléfono: 004561397432
          • Correo electrónico: perpet@rm.dk
        • Contacto:
          • Thea Grønfeldt, Psychiatrist
          • Número de teléfono: 00457847 9258
          • Correo electrónico: theafaer@rm.dk
        • Investigador principal:
          • Pernille Kølbæk, MD PhD
      • Viborg, Dinamarca
        • Regional Psychiatry Central Jutland
        • Contacto:
          • Pernille Kølbæk, MD PhD
          • Número de teléfono: 004561397432
          • Correo electrónico: perpet@rm.dk
        • Investigador principal:
          • Ana Lisa Carmo, Psychiatrist
        • Contacto:
          • Ana Lisa Carmo, Psychiatrist
          • Número de teléfono: 004561155056
          • Correo electrónico: ANAMAR@rm.dk

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto
  • Adulto Mayor

Acepta Voluntarios Saludables

No

Descripción

Inclusion Criteria:

  • Age 18-70 years
  • ICD-10 criteria for PTSD (F43.1)
  • A minimum total score of 4 (moderately ill) on the Clinical Global Impression-Severity (CGI-S)
  • Likely to be able to complete trial participation (16 weeks) without modifications to psychopharmacological treatment, as per the referring doctor's or psychologist's assessment
  • Participants must be able and willing to abstain from alcohol consumption during the iTBS treatment period, as required by the TMS Safety Checklist.

Exclusion Criteria:

  • Organic mental disorders (F0)
  • Currently fulfills the criteria of Active psychoactive substance use or dependence (F1)
  • Schizophrenia, schizotypal and delusional disorders (F2), manic episode (F30), or bipolar affective disorder (F31); iv) Mental retardation (estimated IQ <70, as per the referring doctor's or psychologist's assessment)
  • Active suicidality
  • Any ongoing involuntary/coercive measures
  • Any contraindications listed on the TMS Safety Checklist

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: EMDR with add-on iTBS
Participants receive weekly Eye Movement Desensitization and Reprocessing (EMDR) therapy for up to 16 weeks. After seven EMDR sessions, treatment response is assessed using the Clinical Global Impression-Improvement scale (CGI-I). Participants with insufficient response receive adjunctive intermittent theta-burst stimulation (iTBS) to the right dorsolateral prefrontal cortex for 20 sessions over 4 weeks while continuing EMDR. Participants with sufficient response continue EMDR treatment alone.
All enrolled participants begin standardized EMDR treatment. Participants who show insufficient clinical improvement after seven EMDR sessions receive adjunctive intermittent theta-burst stimulation (iTBS) while continuing EMDR. Participants who show sufficient improvement continue EMDR alone.
Otros nombres:
  • Behavioral: Eye Movement Desensitization and Reprocessing (EMDR)

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Drop-out
Periodo de tiempo: From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
The primary outcome will be drop-out rates
From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
Treatment completion rates
Periodo de tiempo: From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
The second primary outcome will be treatment completion rates (number of iTBS treatments received out of the planned 20 treatments)
From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Symptom trajectories
Periodo de tiempo: From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
Symptom trajectories, as measured by the Clinician Administered PTSD Scale for DSM-5 (CAPS-5)
From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
Symptom trajectories
Periodo de tiempo: From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
Symptom trajectories, as measured by the PTSD Checklist for DSM-5 (PCL-5)
From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
Symptom trajectories
Periodo de tiempo: From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
Symptom trajectories, as measured by International Trauma Questionnaire (ITQ)
From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
Symptom trajectories
Periodo de tiempo: From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
Symptom trajectories, as measured by the 6-item self-reported Hamilton Depression Rating Scale (HAM-D6-SR)
From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
Adverse event rates
Periodo de tiempo: From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
Adverse event rates, measured by means of the Transcranial Magnetic Stimulation Sensory Questionnaire (TMSens_Q)
From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
Adverse event rates
Periodo de tiempo: Time Frame: From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
Adverse event rates, measured by means of the Aarhus Side Effects Assessment Scale (ASAQ)
Time Frame: From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
Changes in mental well-being
Periodo de tiempo: From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
Mental well-being as measured by the World Health Organization 5-item well-being scale (WHO-5)
From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Colaboradores

Investigadores

  • Silla de estudio: Pernille Kølbæk, Aarhus University Hospital
  • Investigador principal: Ana Lisa Carmo, Aarhus University Hospital

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de julio de 2026

Finalización primaria (Estimado)

1 de junio de 2027

Finalización del estudio (Estimado)

1 de junio de 2027

Fechas de registro del estudio

Enviado por primera vez

16 de junio de 2026

Primero enviado que cumplió con los criterios de control de calidad

7 de julio de 2026

Publicado por primera vez (Actual)

9 de julio de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

9 de julio de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

7 de julio de 2026

Última verificación

1 de julio de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • 2502681

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .